UNSPSC 51384206: Fenoprofen calcium anhydrous

This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C15H13O3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8R95A3O51K, chemically known as benzeneacetic acid, .alpha.-methyl-3-phenoxy-, calcium salt (2:1), but more generally known as fenoprofen calcium anhydrous, which bears US NIH Compound Identifier 64746. European Medicines Agency schedules fenoprofen calcium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07578MIG.

Most nations, for tariff purposes, schedule fenoprofen calcium anhydrous under HS 29189900. SMILES: CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].[CA+2].

UNSPSC 51384206 Fenoprofen calcium anhydrous, a Commodity code, shows minimal alignment with recent state and local procurement activity. The three recent opportunities in the dataset—a Seminole County, Florida naloxone and drug deactivation systems IFB, a Texas Health and Human Services Commission direct-to-manufacturer prescription RFI, and a Minnesota Multistate Cooperative Purchasing Alliance generic pharmaceuticals and OTC products RFP—span community health opioid-response procurement, prescription fulfillment strategy, and bulk generic medication supply respectively. None of these solicitations reference fenoprofen calcium anhydrous or other nonsteroidal anti-inflammatory drugs by specific active pharmaceutical ingredient. The code's nominal scope does not match the actual work being solicited under it in the recent opportunities block.

State and local procurement activity under this code designation appears to reflect either a tagging inconsistency or dormant use of the specific fenoprofen calcium anhydrous commodity code in recent contract cycles. Issuing bodies with current pharmaceutical and medical supply procurement activity—county health departments, state health commissions, and multistate cooperative purchasing alliances—are pursuing broader pharmaceutical categories (naloxone, generic multi-source drugs, direct-manufacturer relationships) rather than single-ingredient dosage forms. Geographic activity in the recent record spans Florida, Texas, Minnesota, and Oregon, but none explicitly targets fenoprofen calcium anhydrous products. A firm evaluating this code should confirm whether current state and local demand for this specific pharmaceutical exists outside the recent-opportunity dataset or whether procurement has shifted to aggregated generic or therapeutic categories that obscure ingredient-level codes.